<h2></h2>
The American Health Information Management Association (AHIMA) announced today that OU Medicine has chosen to use the AHIMA library of physician query templates available in Artifact Health’s mobile physician query platform.

As the leading source of health information management (HIM) education, training and policy making, AHIMA updated in 2019 its Guidelines for Achieving a Compliant Query Practice to establish and support industry-wide best practices for the function of clinical documentation querying. Through its partnership with Artifact Health, AHIMA is able to provide standardized, electronic query templates and educational guidance for physicians, CDI professionals and HIM professionals. These templates help clarify clinical documentation and ultimately improve the quality of patient records.

>”…[W]e have been able to completely transform our query process.”
– Jennifer Dhooge, RHIA, CCS, CDIP, CRC, OU Medicine director of HIM

“We are thrilled to work with AHIMA and Artifact to be able to standardize physician queries across our system while ensuring compliance and improving the quality of our patient records,” said Jennifer Dhooge, RHIA, CCS, CDIP, CRC, OU Medicine director of HIM, coding and CDI. “Coupled with the innovative mobile query platform provided by Artifact, we have been able to completely transform our query process.”

“AHIMA is pleased that OU Medicine is taking advantage of our library of physician query templates,” said AHIMA CEO Wylecia Wiggs Harris, PhD, CAE. “Our alliance with Artifact Health continues to decrease administrative burdens for hospitals and health systems, while boosting the accuracy of patient records. I’m proud our strategic vision is helping to improve patient outcomes and save resources.”

Artifact Health provides the first and only mobile platform that streamlines the physician query process. Traditionally, the query process can be onerous and time-consuming for physicians, clinical documentation specialists and medical coders. With Artifact Health’s HIPAA-compliant, cloud-based, mobile query platform, physicians respond to a query compliantly in seconds with as few as three taps on their smartphone.

“We are excited to provide OU Medicine with an opportunity to work with AHIMA experts to standardize compliant query workflow,” said Marisa MacClary, co-founder and CEO of Artifact Health. “Artifact customers are committed and passionate about reducing query burden on their busy providers. By adding AHIMA’s world-class knowledge and best practices to query workflow, our customers ensure queries and educational guidance are accurate, compliant, and current.”

**About Artifact Health**
Artifact Health provides the first and only mobile platform that streamlines the physician query process so hospitals can improve the quality of patient records and ensure full reimbursement for services. Already in use by thousands of physicians, Artifact simplifies a traditionally time-consuming, multi-step process allowing physicians to respond to queries anytime, anywhere in seconds. By shortening average physician response time to queries by 20x, Artifact helps CDI specialists and coders receive more accurate responses faster, which can translate into capturing missed reimbursement for hospitals and ensuring more accurate medical records for patients. Visit www.artifacthealth.com to learn more.

**About AHIMA**
The American Health Information Management Association (AHIMA) is a global nonprofit association of health information (HI) professionals. AHIMA represents professionals who work with health data for more than one billion patient visits each year. AHIMA’s mission of empowering people to impact health drives our members and credentialed HI professionals to ensure health information is accurate, complete, and available to patients and providers. Our leaders work at the intersection of healthcare, technology, and business, and are found in data integrity and information privacy job functions worldwide. Visit www.ahima.org for more information.

**About OU Medicine**
OU Medicine — along with its academic partner, the University of Oklahoma Health Sciences Center — is the state’s only comprehensive academic health system of hospitals, clinics and centers of excellence. With 11,000 employees and more than 1,300 physicians and advanced practice providers, OU Medicine is home to Oklahoma’s largest physician network with a complete range of specialty care. OU Medicine serves Oklahoma and the region with the state’s only freestanding children’s hospital, the only National Cancer Institute-Designated Stephenson Cancer Center and Oklahoma’s flagship hospital, which serves as the state’s only Level 1 trauma center. OU Medicine is the No. 1 ranked hospital system in Oklahoma, and its oncology program at Stephenson Cancer Center and OU Medical Center ranked in the Top 50 in the nation, in the 2019-2020 rankings released by U.S. News & World Report. OU Medicine’s mission is to lead healthcare in patient care, education and research. To learn more, visit www.oumedicine.com.

AUSTIN, TX – February 8, 2022 – Iodine Software has been named the market leader for CDI Software by KLAS Research in their 2022 Best in KLAS: Software and Services Report. Iodine ranked #1 with a score of 91.2, and this achievement follows AwareCDI™ receiving the top overall performance score in the 2021 KLAS Clinical Documentation Improvement (CDI) Report. In 2021 Iodine Software acquired Chartwise, who was also a top performer in the 2022 KLAS report with a score of 89.2.

The Best in KLAS report recognizes software and services companies who excel at helping healthcare professionals improve patient care. The report noted that 95% of respondents answered “yes,” both Iodine AwareCDI and Chartwise “avoid charging for every little thing” and AwareCDI was “part of long-term plans”. All rankings are a direct result of the feedback of thousands of providers over the last year. “This award reflects our commitment to delivering the most powerful, predictive tools as well as exceptional service and support to every client, working hard to be responsive, timely and proactive to our clients’ unique needs, said William Chan, CEO and co-founder of Iodine. “This Best in KLAS award is especially meaningful because it reflects the positive experiences of our clients.”

Iodine’s AwareCDI solution empowers organizations to scale their most precious and limited resources, their clinical talent, through automation of clinical work that otherwise would require highly trained and specialized staff to complete. Clients report higher productivity and job satisfaction for CDI teams and physicians, complete and accurate documentation, and capturing more earned revenue. The Iodine AwareCDI Suite helps 550+ hospitals to collectively recognize $1.5 billion¹ in additional appropriate reimbursement annually.

According to KLAS Research President Adam Gale, “The Best in KLAS report and the awards it contains set the standard of excellence for software and services firms. The Best in KLAS award serves as a signal to provider and payer organizations that they should expect excellence from the winning vendors.”

To download the full 2022 KLAS Clinical Documentation Improvement Report, visit : https://klasresearch.com/report/2022-best-in-klas-awards-software-and-professional-services/2770

KLAS Research will honor Iodine and the other segment winners for 2022 in a ceremony held at HIMSS March 14th.

About Iodine Software:
Iodine is an enterprise AI company that is championing a radical rethink of how to create value for healthcare professionals, leaders, and their organizations: automating complex clinical tasks, generating insights and empowering intelligent care. Iodine’s powerful predictive engine complements the skills and judgment of healthcare professionals by interpreting raw clinical data to generate real-time, highly focused, predictive insights that clinicians and hospital administrators can leverage to dramatically augment the management of care delivery – facilitating critical decisions, scaling clinical workforces through automation, and improving the financial position of health systems. For more information, please visit iodinesoftware.com.

About KLAS Research:
KLAS has been providing accurate, honest, and impartial insights for the healthcare IT (HIT) industry since 1996. The KLAS mission is to improve the world’s healthcare by amplifying the voice of providers and payers. The scope of our research is constantly expanding to best fit market needs as technology becomes increasingly sophisticated. KLAS finds the hard-to-get HIT data by building strong relationships with our payer and provider friends in the industry. Learn more at klasresearch.com

_{1. Figures are based on a $6,000 modeled base rate and actual measured MCC capture performance from the 2019 Iodine Performance Cohort Analysis of 339 facilities that compared measured MCC capture and CMI impact for the Iodine usage period 9/1/2018-8/31/2019 against pre-Iodine baseline performance.}

AUSTIN, TX and BOSTON, MA – December 1, 2021 – Iodine Software (“Iodine” or the “Company”), a leading healthcare AI company, today announced a strategic growth investment from Advent International (“Advent”), one of the largest and most experienced global private equity investors. Advent will acquire a significant stake in Iodine in a transaction that values the business at over $1 billion. Bain Capital Ventures (“BCV”) and Silversmith Capital Partners (“Silversmith”), which invested in the Company in 2018, will remain shareholders. Financial terms were not disclosed.

“Utilizing advancing technology to scale hospital resources, ease administrative burden, and maximize reimbursement is more important than ever,” said William Chan, Iodine’s CEO and co-founder. “We’ve always been committed to building the most powerful, predictive tools available. This investment provides access to capital for expansion and growth strategies so that we can innovate faster and find more ways to empower healthcare leaders to meet with confidence the delicate balance of quality, efficiency, and system financial resilience.”

Iodine Software provides the leading clinical AI solution for highly accurate capture of patient documentation. The Company’s platforms are trusted by more than 800 hospitals and are used by more than 80,000 healthcare providers nationwide.

Iodine’s AwareCDI solution recently received the top overall performance score in the 2021 KLAS Clinical Documentation Improvement Report. The company also recently completed the acquisitions of Artifact Health and ChartWise to broaden its market reach, bolster its portfolio and deliver a comprehensive query transformation solution that solves a critical physician pain point.

“We are pleased to be partnering with Iodine Software as it continues to experience rapid growth across hospitals and health systems,” said Carmine Petrone, a Managing Director on Advent’s Healthcare team. “Iodine’s world-class AI innovation engine and strong customer focus underpin the company’s ability to deliver a best-in-class product with highly differentiated value.” Lauren Young, a Managing Director on Advent’s technology team, added: “With our extensive experience scaling software and healthcare businesses, we look forward to working with Bain Capital Ventures and Silversmith Capital Partners to support William and the entire Iodine team to continue driving innovation and building a leading AI/machine learning-driven revenue cycle management platform.”

This investment will empower Iodine to invest further in its AI engine, CognitiveML, to power new and additional products in other strategic areas of care delivery for health systems.

“We were excited to partner with the founders of Iodine back in 2018 as their first institutional investor, and are even more thrilled to partner with Advent and the Iodine team to support the next phase of growth,” said Jeff Crisan, Managing Partner at Silversmith Capital Partners. Yumin Choi, partner at Bain Capital Ventures, added, “We saw the enormous potential its AI-powered software would provide to hospitals going through digital transformations. With this strategic investment, Iodine will have the opportunity to reach more hospital professionals, resulting in better care for patients across the US.”

Over the past 30+ years, Advent has invested or committed more than $11 billion in 88 technology companies and $10 billion in 51 healthcare companies, including health tech, software and provider businesses.

Deutsche Bank served as exclusive financial advisor to Iodine and Queen Saenz + Schutz PLLC served as the Company’s legal advisors. For Advent, Evercore and TripleTree served as financial advisors and Weil, Gotshal & Manges LLP served as legal counsel.

 About Iodine Software

Iodine is an enterprise AI company that is championing a radical rethink of how to create value for healthcare professionals, leaders, and their organizations: automating complex clinical tasks, generating insights and empowering intelligent care. Iodine’s powerful predictive engine complements the skills and judgement of healthcare professionals by interpreting raw clinical data to generate real-time, highly focused, predictive insights that clinicians and hospital administrators can leverage to dramatically augment the management of care delivery – facilitating critical decisions, scaling clinical workforces through automation, and improving the financial position of health systems. For more information, please visit iodinesoftware.com.

About Advent International

Founded in 1984, Advent International is one of the largest and most experienced global private equity investors. The firm has invested in over 380 companies in 42 countries, and as of June 30, 2021, had $81 billion in assets under management. With 15 offices in 12 countries, Advent has established a globally integrated team of over 245 investment professionals across North America, Europe, Latin America and Asia. The firm focuses on investments in five core sectors, including business and financial services; healthcare; industrial; retail, consumer and leisure; and technology. After more than 35 years dedicated to international investing, Advent remains committed to partnering with management teams to deliver sustained revenue and earnings growth for its portfolio companies. For more information, visit www.adventinternational.com or www.linkedin.com/company/advent-international.

About Bain Capital Ventures

Bain Capital Ventures partners with disruptive founders to accelerate their ideas to market. BCV invests from seed to growth in startups driving transformation across industries, from SaaS, infrastructure software and security to fintech and healthcare to commerce and consumer tech. The firm has helped launch and commercialize more than 365 companies, including Attentive, Digital Currency Group, DocuSign, Flywire, Jet.com, LinkedIn, Redis Labs, Rent the Runway, SendGrid, and SurveyMonkey. BCV has $9.2 billion in assets under management with offices in San Francisco, New York, Boston, and Palo Alto. Follow the firm via LinkedIn and Twitter.

About Silversmith Capital Partners

Founded in 2015, Silversmith Capital Partners is a Boston-based growth equity firm with $2.0 billion of capital under management. Silversmith’s mission is to partner with and support the best entrepreneurs in growing, profitable technology and healthcare companies. Representative investments include ActiveCampaign, Appfire, Centauri Health Solutions, DistroKid, Impact, Iodine Software, LifeStance Health, Panalgo, Unily, Upperline Health, Validity, and Webflow. The partners have served on the boards of numerous successful growth companies including ABILITY Network, Archer Technologies, Dealer.com, Liazon, Liberty Dialysis, MedHOK, Passport Health, SurveyMonkey, and Wrike. For more information about Silversmith, please visit www.silversmith.com.

Media Contacts

 For Iodine Software

Amanda Wratchford

press@iodinesoftware.com 

For Advent International

Anna Epstein or Sophia Templin

Finsbury Glover Hering

Adventinternational-US@finsbury.com

For Bain Capital Ventures

Kristi Essick

kristi@archwaypr.com

For Silversmith Capital Partners

Kate Castle

kate@silversmith.com

 

Expansion of Artifact Health mobile physician query solution rolled out across the eight-hospital system.

After a successful pilot of the first and only mobile platform that streamlines the physician query process, Mount Sinai Health System (MSHS) will strengthen and expand its collaboration with Artifact Health, a leading innovator in physician-centric clinical documentation improvement (CDI) solutions. MSHS will expand the Artifact mobile query platform throughout its system, one of New York City’s largest integrated healthcare delivery systems, encompassing eight hospitals, a leading medical school, and over 450 ambulatory practices throughout greater New York, New Jersey and Palm Beach, FL.

The Mount Sinai Hospital and Mount Sinai Queens served as pilot sites for Artifact Health’s mobile physician query platform in January of this year and will roll out throughout the system this September. The platform makes it easier for physicians to respond to clinical questions from CDI specialists and medical coders resulting in higher-quality documentation, proper reimbursement and more accurate publicly reported quality outcomes.

Stephen Teitelbaum, MD, Medical Director for Clinical Documentation Quality Improvement and Vice President of Clinical Data Integrity at MSHS said, “Expanding the Artifact platform is part of a larger strategy at Mount Sinai to reduce physician burnout by providing technologies that engage physicians with faster and easier administrative workflows. One of the key priorities emerging from our massive effort battling the pandemic in New York City is to deploy technologies that ease burden on physicians and give them back time to care for patients. During the pilot, Mount Sinai physicians found Artifact Health’s technology to be convenient, fast and easy to use which went into our decision to deploy across our hospitals.”

“As Mount Sinai accelerates our transition to business models focused on population health management, our physicians require innovative tools enabling quality clinical documentation in the medical record,” said Luke Hermann, MD, Senior Vice President, Clinical Business Intelligence and Implementation at MSHS and Associate Professor in Emergency Medicine at Icahn School of Medicine at Mount Sinai. “Our goal is to accurately and completely capture the health status of our patients and the high-quality care they receive.”

Traditionally, the query process is onerous and time-consuming for physicians, clinical documentation specialists and medical coders. With Artifact Health’s HIPAA-compliant, cloud-based, mobile query platform, physicians respond to a query compliantly in seconds with as few as three taps on their smartphone. By engaging physicians with a faster and easier process, Artifact drives improvements in hospital and physician coding accuracy and publicly reported quality measures.

“We are extremely proud to partner with Mount Sinai Health System to help their physicians more easily document the high-quality care they provide,” said Marisa MacClary, co-founder and CEO of Artifact Health. “We’re looking forward to continuing to collaborate with Mount Sinai in ways that support participation in value-based care models without imposing additional documentation burden on physicians.”

**About Artifact Health**
Artifact Health provides the first and only mobile platform that streamlines the physician query process so hospitals can improve the quality of patient records and ensure full reimbursement for services. Already in use by thousands of physicians, Artifact simplifies a traditionally time-consuming, multi-step process allowing physicians to respond to queries anytime, anywhere in seconds. By shortening average physician response time to queries by 20x, Artifact helps CDI specialists and coders receive more accurate responses faster, which can translate into millions of dollars in revenue for hospitals. Visit www.artifacthealth.com to learn more.

Acquisition combines “Best in KLAS” workflow with Iodine’s market-leading clinical AI.

JUNE 10, 2021 — AUSTIN, Texas. — Iodine Software, a leading healthcare AI company, today announced it has acquired CDI Software and Services company ChartWise Medical Systems, overall winner of the 2021 Best in KLAS Award for CDI. The acquisition brings together two industry leaders and expands Iodine’s clinical predictions to more than 800 hospitals and health systems.

ChartWise represents Iodine’s second acquisition this year after recently acquiring mobile-based physician engagement platform Artifact Health. Iodine has experienced rapid growth over the last decade by applying its CognitiveML Engine to solve key health system mid-cycle revenue leakage challenges — the first healthcare application of its machine-learning technology. Today’s acquisition announcement further signals Iodine’s commitment to expand its machine-learning technology to the market.

“ChartWise has been a top performer in addressing the needs of CDI teams for many years. Not only do they open up access for Iodine to a whole new set of hospitals and health systems, they also bring capabilities and new product innovations that will expand our offerings to the clinical documentation teams we serve,” said William Chan, co-founder and CEO of Iodine Software.

Iodine selected ChartWise for its “Best in KLAS” performance in ensuring clinical documentation integrity, its expanded capabilities, which include an outpatient application, and the overall value it brings to smaller health systems. The acquisition also expands Iodine’s reach into a market segment the company had not previously accessed and establishes a foothold in several global markets. Additionally, today’s acquisition signals Iodine’s rapidly advancing strategy to expand its machine-learning technology to serve the broader healthcare market.

Iodine and ChartWise both were recently recognized by KLAS Research as top-performing CDI companies. KLAS is trusted among healthcare professionals as impartial research and performance benchmarking. In its most recent KLAS Clinical Documentation Improvement 2021 Report, Iodine earned the highest overall performance score. ChartWise was awarded “Best in KLAS” among CDI software, representing its fourth consecutive win in the category. The company has an “A” rating or better in every KLAS metric, demonstrating its customer-centric product innovation and responsive service.

“The key to success in the CDI market today is all about product depth and automation across the entire inpatient and outpatient continuum of care. Providers and payers need smart, proven workflow tools to optimize results for CDI specialists, physicians, and quality, HIM, and revenue cycle leaders. Iodine customers now have the benefit of the top three best-in-breed CDI solutions: Iodine, ChartWise, and Artifact — all under one umbrella,” said Steven J. Mason, Jr., President and CEO of ChartWise Medical Systems. “We are very enthusiastic about the opportunities this acquisition provides for our collective customers and other leading CDI-driven healthcare organizations.”

The ChartWise team will join Iodine immediately. Moving forward, the combined team will continue delivering innovative healthcare solutions utilizing machine-learning technology to help organizations achieve their desired financial, operational, and quality outcomes. ChartWise CEO Steven J. Mason, Jr. will join Iodine as Executive Vice President, ChartWise, and will lead the ChartWise platform.

Queen Saenz + Schutz PLLC is acting as legal advisor to Iodine Software. Canaccord Genuity acted as the exclusive financial advisor to ChartWise.

About Iodine Software
Iodine Software is a healthcare AI company that has pioneered a new machine learning approach — Cognitive Emulation — to help healthcare finance leaders build resilient organizations. Founded in 2010, Iodine’s technology unifies clinical concepts, evidence-based medicine, and deep machine learning to power revenue cycle solutions that maximize revenue capture and data accuracy. To date, the Iodine AwareCDI™ Suite has helped more than 500 hospitals recognize $1.5 billion in additional appropriate reimbursement annually. To learn more, visit iodinesoftware.com.

About ChartWise
ChartWise Medical Systems, Inc., based in Wakefield, Rhode Island, specializes in cloud-based solutions for Computer-Assisted Clinical Documentation Improvement. AI-driven, integrated, and comprehensive, ChartWise’s scalable Software as a Service (SaaS) assists physicians and clinical documentation specialists and features prioritization, electronic queries, flexible workflow, robust reporting, and denials prevention. Developed by renowned physician Jon Elion, M.D., ChartWise is the only CDI software designed by CDI customers for CDI customers, offering reduced risk, actionable data, and a proven fast ROI. For more information, visit ChartWisemed.com.

Acquisition enables Iodine to add mobile-based physician query capabilities, addressing key health system mid-cycle revenue leakage challenge

AUSTIN, Texas, May 25, 2021 (Newswire.com) – Iodine Software, a leading healthcare AI company, today announced it has acquired physician engagement platform company Artifact Health. The acquisition brings together two industry leaders and expands Iodine’s clinical predictions and insights platform beyond clinical documentation improvement (CDI) teams to directly engage physicians through Artifact’s HIPAA-compliant mobile platform.